Janssen Pharmaceutica N.V. Release: New Data Show XEPLION® Significantly Delays Time To Relapse Compared To Treatment As Usual With Oral Antipsychotic Monotherapy

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Janssen Pharmaceutica NV has announced results of the Prevention of Relapse With Oral Antipsychotics Versus Injectable Paliperidone Palmitate (PROSIPAL) study* at the 22nd European Congress of Psychiatry in Munich, Germany, 1-4 March 2014. Data showed that XEPLION® (paliperidone palmitate), a once-monthly, long-acting therapy, significantly lengthened the time to relapse during the two year treatment phase, as well as significantly lowering relapse rates in people with schizophrenia, compared to treatment as usual with the investigator’s choice of oral antipsychotic treatment.1

Help employers find you! Check out all the jobs and post your resume.

Back to news